Evidence map›Paper›PMID 39879572›Full record

Trial reportNeurology2025

Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults.

Zhen Zhou, Chris Moran, Anne M Murray, Sophia Zoungas, Costan Magnussen, Trevor T-J Chong, Raj C Shah, Kerry M Sheets, Mark Nelson, Chao Zhu and 10 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Obesity, Hypertension and Brain Health.Current hypertension reports · 2025
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zhen ZhouSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-0835-8686
Chris MoranSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0003-1872-3314
Anne M MurrayBerman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Division of Geriatrics, Department of Medicine Hennepin HealthCare, Minneapolis, MN.ORCID 0000-0002-2787-8433
Sophia ZoungasSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0003-2672-0949
Costan MagnussenBaker Heart and Diabetes Institute, Melbourne, Australia.
Trevor T-J ChongTurner Institute for Brain & Mental Health, Monash University, Notting Hill, Australia.ORCID 0000-0001-7764-3811
Raj C ShahDepartment of Family and Preventive Medicine and Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL.ORCID 0000-0001-9706-9730
Kerry M SheetsBerman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Division of Geriatrics, Department of Medicine Hennepin HealthCare, Minneapolis, MN.ORCID 0000-0002-3492-2404
Mark NelsonMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.ORCID 0000-0001-9941-7161
Chao ZhuSchool of Translational Medicine, Monash University, Melbourne, Australia.ORCID 0000-0003-3951-7501
Andrew M TonkinSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0001-5291-0610
Stella TalicSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Michael E ErnstDepartment of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, Iowa City.ORCID 0000-0003-0267-4888
Suzanne G OrchardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0003-0211-3183
John J McNeilSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-1049-5129
Rory WolfeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-2126-1045
Robyn L WoodsSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0003-1249-6149
Johannes T NeumannSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Peng QiuDepartment of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Joanne RyanSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-7039-6325

Funding

AHRQ HHS P30 HS029744
6 · The paper itself

Abstract

BACKGROUND AND

objectivesLipid metabolism in older adults is affected by various factors including biological aging, functional decline, reduced physiologic reserve, and nutrient intake. The dysregulation of lipid metabolism could adversely affect brain health. This study investigated the association between year-to-year intraindividual lipid variability and subsequent risk of cognitive decline and dementia in community-dwelling older adults.

methodsASPirin in Reducing Events in the Elderly (ASPREE) was a randomized trial of aspirin, involving 19,114 participants aged 65 years and older from Australia and the United States who were free of dementia and major cognitive impairment. ASPREE-eXTension is the post-trial observational follow-up of participants, currently to a maximum of 11 years. This post hoc analysis included participants who had lipid levels measured at baseline and in years 1, 2, and 3. Year-to-year variability in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglycerides over the first 3 years was quantified using variability independent of the mean. Individuals who initiated or discontinued lipid-lowering therapy during this period were excluded. Multivariable Cox proportional hazards regression was used to analyze associations with incident dementia, adjudicated by expert panels, and cognitive impairment with no dementia (CIND) confirmed by a battery of cognitive tests, occurring after year 3. A linear mixed model was used for assessing the association with changes in 4 cognitive function domains, including global, memory, processing speed, verbal fluency, and a composite score from baseline to the end of follow-up.

resultsThe analysis included 9,846 individuals (median [interquartile range] age: 73.9 [71.7-77.3] years, 54.9% female). 509 incident dementia and 1,760 CIND events were recorded over a median follow-up of 5.8 and 5.4 years after variability assessment. The hazard ratios (95% CI) comparing the highest and lowest quartiles of TC and LDL-c variability were 1.60 (1.23-2.08) and 1.48 (1.15-1.91) for dementia and 1.23 (1.08-1.41) and 1.27 (1.11-1.46) for CIND. Higher TC and LDL-c variability was also associated with a faster decline in global cognition, episodic memory, psychomotor speed, and the composite score (all DISCUSSION: Tracking variability of TC and LDL-c may serve as a novel biomarker of incident dementia and cognitive decline in older adults.

Indexed as

Cognitive DysfunctionDementiaAgedAged, 80 and overAspirinAustraliaFemaleFollow-Up StudiesHumansIndependent LivingMaleRisk FactorsTriglyceridesUnited StatesAspirinTriglycerides

Identifiers

PMID39879572
PMCPMC11774555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.